Viewing Study NCT01453192


Ignite Creation Date: 2025-12-24 @ 3:35 PM
Ignite Modification Date: 2025-12-30 @ 7:07 AM
Study NCT ID: NCT01453192
Status: COMPLETED
Last Update Posted: 2016-07-12
First Post: 2011-10-03
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Renal Transplantation and Raltegravir in HIV-Infected Patients
Sponsor: ANRS, Emerging Infectious Diseases
Organization:

Study Overview

Official Title: National, Multicenter, Phase III Prospective Trial About Clinical and Immunological Follow-up After Renal Transplantation in HIV-1 Infected Patients With End Stage Chronic Renal Insufficiency
Status: COMPLETED
Status Verified Date: 2016-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ANRS153TREVE
Brief Summary: The aim of this study is to evaluate the incidence of acute renal graft rejection 6 months after transplantation in HIV-infected patients under three antiretroviral drugs regimen including Raltegravir.
Detailed Description: Antiretroviral treatment of HIV-1 Infection might interact with immunosuppressive treatments which increase rejection of renal graft incidence.

In addition HIV infection may be modified together with cardiovascular risk. Patients participating to this study will receive after transplantation antiretroviral regimen including Raltegravir.

Raltegravir treatment does not interact with immunosuppressive drugs and thus seems to be the treatment of choice to be associated with immunosuppressive drugs.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
ANRS 153 TREVE REGISTRY ANRS View